Status:
COMPLETED
Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD)
Lead Sponsor:
University of Washington
Collaborating Sponsors:
University of Texas
University of Pennsylvania
Conditions:
Chronic Posttraumatic Stress Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Posttraumatic stress disorder (PTSD) is a condition that involves intense memories of a traumatic event and intense, persistent feelings of anxiety. There are several effective therapies for PTSD, but...
Detailed Description
The psychotherapy the investigators are offering in this study is a type of cognitive behavioral therapy called imaginal exposure. In imaginal exposure, the investigators encourage the client to appro...
Eligibility Criteria
Inclusion
- Current primary PTSD diagnosis based on DSM-IV criteria, with a minimum duration of 12 weeks since the traumatic event.
- Between the age of 18 and 65.
Exclusion
- Current diagnosis of schizophrenia, delusional disorder, or organic mental disorder as defined by the DSM-IV.
- Current diagnosis of bipolar disorder, depression with psychotic features, or depression severe enough to require immediate psychiatric treatment (i.e., serious suicide risk with intent and plan).
- Current diagnosis of alcohol or substance dependence within the 3 previous months.
- Unwilling or unable to discontinue current trauma-focused psychotherapy or psychotropic medication (at least 1 month medication free).
- Ongoing intimate relationship with the perpetrator (in assault-related PTSD cases).
- Unstable cardiovascular, autoimmune, endocrine, neurological, renal, hepatic, retinal, gastrointestinal, or hematological disorder or current seizure disorder.
- Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception for the duration of active treatment.
- A history of hypersensitivity or allergy to MB.
- Any condition possibly affecting drug absorption (e.g., gastrectomy).
- Glucose-6-phosphate dehydrogenase deficiency.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that, in the judgment of the Medical Directors, would make the participant inappropriate for entry.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT01188694
Start Date
September 1 2009
End Date
April 1 2013
Last Update
June 14 2017
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
2
University of Texas
Austin, Texas, United States, 78712
3
University of Washington
Seattle, Washington, United States, 98195